KRAS and non-small cell lung carcinoma: Two covalent inhibitors of KRAS, sotorasib (AMG 510) [11, 12] and adagrasib (MRTX 849) [13, 14], have been approved by The Food and Drug Administration (FDA) for the treatment of patients with advanced NSCLC carrying KRAS G12C mutation, and over ten follow-up drugs have entered clinical trials.